Genzyme’s Next-Gen Dialysis Drug Approved

Genzyme (NASDAQ: GENZ) announced that it has gained FDA approval for Renvela (sevelamer carbonate), a drug that helps keep blood levels of phosphorus from getting too high in patients on dialysis. The new drug is a next-generation version of a similar Genzyme drug approved in 1998.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy